UBS maintains Buy rating, $265 target on Inspire Medical stock

On Monday, UBS analyst Danielle Antalffy maintained a Buy rating and a $265.00 price target on Inspire Medical Systems (NYSE:INSP), representing a significant upside from the current price of $187.68. Antalffy’s commentary followed recent meetings with the company’s management, which increased her confidence in the firm’s prospects. According to InvestingPro data, analyst targets range from $190 to $270, with a strong consensus recommendation of 1.82 (Buy). The discussions highlighted that concerns about Inspire 5 Reimbursement might be overstated, despite a reduction in physician fees.

Inspire Medical Systems, which specializes in medical devices for the treatment of obstructive sleep apnea, has been subject to scrutiny over reimbursement rates for its Inspire 5 therapy. The analyst pointed out that while the lower physician fee, now approximately $600 compared to the previous $800, could impact the adoption rate among ear, nose, and throat specialists (ENTs), the ease of the implant procedure might lead to a higher willingness to perform more surgeries.

Moreover, the company’s competitive edge was emphasized during the meetings. Management conveyed that Inspire Medical (TASE:BLWV)’s strong position in the market is not only due to its technological advancements but also because of the comprehensive service and support it offers to its healthcare providers. Financial metrics support this strong position, with InvestingPro data showing impressive revenue growth of 28.49% and an industry-leading gross profit margin of 84.68%. The company maintains a healthy balance sheet with a current ratio of 7.13 and operates with minimal debt. This includes a range of services from ENTs to sleep physicians, which, according to the analyst, contributes to a wider competitive moat than might be apparent.

Antalffy’s reiteration of the Buy rating and price target suggests that the analyst sees Inspire Medical’s current stock value as underappreciated by the market. The company’s focus on high-touch service and support is expected to foster stronger relationships with physician customers and potentially drive further growth.

Investors will likely monitor Inspire Medical Systems’ performance closely, particularly regarding how the changes in reimbursement and the company’s competitive strategies will affect its market share and financial results. The UBS analyst’s perspective provides a positive outlook, maintaining that the company’s unique approach to customer support will continue to be a significant factor in its success. While currently trading slightly above its Fair Value according to InvestingPro analysis, the company’s strong financial health score of "GREAT" and robust growth metrics suggest potential for continued success. For deeper insights into Inspire Medical’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with 13 additional ProTips and extensive financial metrics.

In other recent news, Inspire Medical Systems has reported its fourth-quarter earnings, which have surpassed expectations. The company achieved a notable beat on earnings per share (EPS), exceeding consensus estimates by 57%, and its revenue aligned with prior projections. Analysts from RBC Capital Markets reaffirmed an Outperform rating, highlighting the company’s strong performance and setting a price target of $260. UBS also maintained a Buy rating with a target of $265, citing the company’s robust financial health and potential for continued growth. Despite some legal scrutiny from a Department of Justice investigation, UBS views any resultant stock price dip as a potential buying opportunity.

Truist Securities adjusted its price target for Inspire Medical to $235, maintaining a Buy rating, while acknowledging the DOJ’s Civil Investigative Demand as a potential concern. Morgan Stanley (NYSE:MS) reduced its price target to $220 but kept an Overweight rating, expressing confidence in the company’s conservative guidance. Piper Sandler, too, maintained an Overweight rating with a $233 target, noting the company’s strong profit and loss leverage despite the DOJ investigation. Inspire Medical’s guidance for 2025 includes a revenue target of $940-955 million and an EPS range of $2.10 to $2.20, both above consensus estimates, reflecting the company’s confidence in its growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.